Atrial fibrillation (AF) is the most common arrhythmia in the general population and a frequent postoperative complication of cardiac surgery. AF is now widely recognized as a risk factor for stroke and other thromboembolic complications and heart failure. This leads to a substantial disease burden and significant medical costs. Although many studies have examined the impact of AF on the perioperative period, none has managed to present compelling data that support an independent association between postoperative AF and late mortality. Despite attempts to account for confounding, it remains a distinct possibility that AF is as associated with mortality as with potentially fatal comorbidities. Previously published studies have not provided plausible direct mechanisms that link postoperative AF with late mortality. In addition, the causes of death have not been investigated. In this study, we aimed to ascertain the impact of AF after coronary surgery on postoperative survival, assessing its prognostic role on cause-specific mortality. Our data have given perspective on the possible role of AF among these patients and the effect of embolic events in causing mortality. See p 1612.
Milrinone Use Is Associated With Postoperative Atrial Fibrillation After Cardiac Surgery
Approximately 500 000 patients undergo cardiac surgery in the United States each year. Postoperative atrial fibrillation is a common complication after surgery that causes morbidity and prolongs hospitalization. Milrinone use on the day of surgery was associated with an increased risk of postoperative atrial fibrillation even after controlling for other risk factors such as age, ejection fraction, and increased pulmonary artery pressure. These findings have clinical and financial implications. Milrinone was administered in 35% of patients in this single-center study. On the basis of the incidence of postoperative atrial fibrillation in the milrinone-treated versus nonexposed patients, similar rates of milrinone use nationally could result in an excess of 56 000 cases of postoperative atrial fibrillation per year, with an attendant excess in postoperative stroke and prolongation of hospital stay. Randomized, prospective studies are needed to assess further the risk of postoperative atrial fibrillation associated with milrinone use. See p 1619. Patients with diabetes mellitus (DM) are at high risk for recurrent cardiovascular events after acute coronary syndrome, in part because of increased platelet reactivity. Patients with DM have also been reported to be more likely to have a poor antiplatelet response to clopidogrel. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated an overall 19% reduction in ischemic events with more intensive antiplatelet therapy with prasugrel compared with clopidogrel, but with more bleeding. Of 13/608 subjects, 3146 had a history of DM. We observed that, despite modern therapy including coronary intervention, DM had an independent adverse effect on clinical outcomes. Moreover, we found that prasugrel was especially efficacious in patients with DM. Although key ischemic end points including the primary end point were significantly reduced among both patients with and without DM, greater absolute and relative reductions were seen in favor of prasugrel among subjects with DM, driven by a 5% absolute and 40% relative reduction in MI. No difference in TIMI major bleeding was observed in patients with DM, whereas a significant increase was observed in patients without DM. Combining safety and efficacy, prasugrel showed a net clinical benefit that was greater for patients with DM (26%) than without DM (8%). These data have implications for the potential use of prasugrel but also in a broader sense underscore the importance of intensive antiplatelet therapy for the growing population of patients with DM and acute coronary syndrome. See p 1626.
Greater Clinical

Does Obesity Modify the Effect of Blood Pressure on the Risk of Cardiovascular Disease? A Population-Based Cohort Study of More Than One Million Swedish Men
Some studies have suggested that increased blood pressure has a stronger effect on the risk of cardiovascular disease in lean than in obese persons, although this is not a universal finding. In a very large population-based cohort study of Ͼ1 million Swedish men, which accumulated 65 611 new cardiovascular disease events during follow-up, we have been able to analyze this unresolved research question with greater precision than has been possible previously. Hazard ratios per 1-SD increase in blood pressure were computed within established categories of body mass index (underweight, normal weight, overweight, or obese) with Cox proportional hazards models. In contrast to the hypothesis, the strongest associations of diastolic blood pressure with cardiovascular disease (hazard ratio 1.18), myocardial infarction (hazard ratio 1.22), and stroke (hazard ratio 1.13) were in fact observed in the obese category. Similar results were apparent for systolic blood pressure. Our results suggest that raised blood pressure should be regarded as an equally important risk factor for cardiovascular disease in both obese individuals and normal-weight and underweight persons. See p 1637.
Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
Aldosterone blockade is effective in reducing all-cause mortality in patients after myocardial infarction complicated by left ventricular dysfunction and heart failure. The use of aldosterone blockade in these patients has been recognized as a class 1 indication in both US and European guidelines; however, many clinicians have been reluctant to adopt this strategy because of the fear of inducing serious hyperkalemia (K ϩ Ն6.0 mEq/L). We analyzed the relationship between serum K ϩ and clinical outcomes in the Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and found a 1.6% absolute increase in serious hyperkalemia and a 4.7% absolute decrease in hypokalemia (K ϩ Ͻ3.5 mEq/L). The baseline predictors of serious hyperkalemia were a K ϩ level Ͼ4.3 mEq/L; an estimated glomerular filtration rate Յ60 mL · Congestive heart failure is a major cause of morbidity and mortality despite recent advances in medical therapy. The most commonly used positive inotropes, ␤-adrenergic agonists and phosphodiesterase inhibitors, exert their positive inotropic effects by stimulating the cAMP-protein kinase A pathway in the myocardium. These agents provide rapid and dramatic improvements in cardiac performance, producing immediate relief of heart failure symptoms. However, the prolonged use of these agents may lead to serious adverse cardiac effects. Therefore, an urgent need exists to identify novel signaling mechanisms regulating cardiac contractility. This report demonstrates the functional importance of 2 members of the mitogen-activated protein kinase (MAPK) family, extracellular signal-regulated kinase 1/2 (ERK1/2) and p38-MAPK, in the acute regulation of cardiac contractility in the intact adult rat heart. Our results reveal that MAPKs play opposing roles in that the ERK1/2-mediated positive inotropic response to endothelin-1 is counterbalanced by simultaneous activation of p38-MAPK. Moreover, our data suggest that inhibition of p38-MAPK may enhance contractility by suppressing the function of phospholamban, the inhibitory protein for the sarcoplasmic reticulum Ca 2ϩ pump. ERK1/2 signaling has been reported to confer protection against stress-induced myocyte apoptosis. A signaling pathway that promotes cardiomyocyte survival while improving contractile function may offer an attractive approach for treating patients with heart failure. Therefore, further studies are required to test the hypothesis that activation of ERK1/2 signaling can eventually rescue the failing heart. See p 1651.
Hereditary Deficiency of Protein C or Protein S Confers Increased Risk of Arterial Thromboembolic Events at a Young Age: Results From a Large Family Cohort Study
Hereditary deficiency of protein S, protein C, or antithrombin is among the most potent risk factors for venous thromboembolism. Whether these deficiencies also are associated with arterial thromboembolism (ATE) is controversial, whereas data increasingly indicate that venous thromboembolism also may predispose for subsequent ATE. Moreover, several studies reported a potential association between major cardiovascular risk factors and venous thromboembolism. In this family cohort study, we assessed the risk of ATE conferred by protein S, protein C, or antithrombin deficiency and investigated whether subjects with a history of venous thromboembolism are at elevated risk for subsequent ATE. Compared with nondeficient family members, subjects with protein S or protein C deficiency had a 4.6-to 6.9-fold higher risk for ATE before 55 years of age. After 55 years of age, the risk for ATE in these subjects was similar to that in nondeficient family members. In contrast, antithrombin deficiency was not related to significantly higher risk for ATE either before or after 55 years of age. Venous thromboembolism was not associated with elevated risk for subsequent ATE. In thrombophilic families, deficiency of protein S and protein C should be considered in atherothrombotic risk assessment before 55 years of age. After 55 years of age, the risk of ATE is most likely overruled by major cardiovascular risk factors (ie, hypertension, hyperlipidemia, and smoking), and deficiency of protein S or protein C may not have additional value in atherothrombotic risk assessment in these families. See p 1659.
